Growth Opportunities and Trends in the Topical Drugs Contract Development And Manufacturing Organization (CDMO) Market: Key Insights for 2025-2034
Get 15% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the topical drugs contract development and manufacturing organization (cdmo) market?
The market size for Contract Development and Manufacturing Organization (CDMO) for topical drugs has experienced fast-paced growth in recent years. It is projected to amplify from $52.9 billion in 2024 to $61.69 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 16.6%. This rapid expansion in the historic period can be linked to the rise in chronic diseases, advancements in drug delivery technologies, cost-effective outsourcing, regulatory requirements, and the boom in the dermatology and cosmetics sector.
What will be the topical drugs contract development and manufacturing organization (cdmo) market size in the future?
The topical drugs contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $113.06 billion in 2029 at a compound annual growth rate (CAGR) of 16.4%. The growth in the forecast period can be attributed to personalized medicine, biologics expansion, increased R and D investments, rising skin disorder prevalence, and advanced manufacturing technologies. Major trends in the forecast period include increasing demand for innovative formulations, advancements in drug delivery technologies, rising investment in dermatological research, a surge in outsourcing by pharmaceutical companies, a focus on personalized medicine, stringent regulatory requirements necessitating specialized expertise, and the growing consumer preference for over-the-counter (OTC) skincare products.
Get your topical drugs contract development and manufacturing organization (cdmo) market report here!
What main drivers are fueling expansion in the topical drugs contract development and manufacturing organization (cdmo) market?
The escalating occurrence of skin conditions is projected to boost the expansion of the topical drugs contract development and manufacturing organization (CDMO) market in future. Skin conditions imply medical issues that impact the skin, resulting in symptoms such as inflammation, itching, and lesions. Various factors like environmental pollution, exposure to UV radiation, lifestyle alterations, microbial infections, and genetic predisposition can be attributed to the escalating occurrence of skin conditions. The services provided by topical drugs contract development and manufacturing organization (CDMO) significantly curbs the prevalence of skin diseases by enabling the development and production of targeted therapies which enhance management and treatment of dermatological issues. For example, Cancer Australia, an Australian-based cancer control agency, reported in January 2024, that there was a substantial rise in skin melanoma cases in Australia between 2019 and 2023, with figures jumping from 15,628 to 18,257. Also, in 2019, there were 9,134 male patients compared to 6,494 females, but by 2023, the numbers escalated to 10,639 males and 7,618 females. As a result, the escalating occurrence of skin conditions is propelling the expansion of the topical drugs contract development and manufacturing organization (CDMO) market.
What key areas define the segmentation of the global topical drugs contract development and manufacturing organization (cdmo) market?
The topical drugs contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Semi-Solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products
2) By Service Type: Contract Development, Contract Manufacturing
3) By Therapeutic Area: Dermatology, Pain Management, Wound Care, Ophthalmology, Other Therapeutic Areas
4) By End-Use: Pharmaceutical Companies, Biopharmaceutical Companies, Other End-Uses
Subsegments:
1) By Semi-Solid Formulations: Creams, Ointments, Gels, Pastes
2) By Liquid Formulations Drugs: Solutions, Suspensions, Emulsions, Lotions
3) By Solid Formulations: Powders, Tablets
4) By Transdermal Products: Patches
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15942&type=smp
Who are the key firms paving the way for growth in the topical drugs contract development and manufacturing organization (cdmo) market?
Major companies operating in the topical drugs contract development and manufacturing organization (CDMO) market are Evonik Industries AG, Eurofins Scientific SE, SGS SA, The Lubrizol Corporation, Lonza Group AG, Catalent Inc., Bora Pharmaceuticals Co. Ltd., Recipharm AB, Pierre Fabre S.A., Piramal Pharma Solutions, Cambrex Corporation, LTS Lohmann Therapie-Systeme AG, PCI Pharma Services, Famar S.A., Contract Pharmaceuticals Limited, UPM Pharmaceuticals Inc., CoreRx Inc., Halo Pharmaceutical Inc., Tapemark Company, Groupe PARIMA Inc., MedPharm Ltd., Tergus Pharma LLC, Dow Development Laboratories LLC, NextPharma Technologies Holding Limited, Tedor Pharma Inc.
What are the key trends shaping the future of the topical drugs contract development and manufacturing organization (cdmo) market?
Leading corporations in the topical drugs contract development and manufacturing organization (CDMO) sector are prioritizing the construction of sophisticated production facilities to maintain their market position. A sophisticated manufacturing facility is distinct as it’s equipped with the latest technology and advanced procedures specifically for creating and manufacturing topical pharmaceutical items. For example, in November 2023, SOHM Inc., a pharmaceutical firm based in the US, introduced a CDMO GMP manufacturing facility. The recently built Carlsbad facility provides extensive area for producing topical products and operating SOHM’s tasks, dedicating 2,500 square feet to the storage of finished products. The facility plans to establish an initial daily production capacity of 500 gallons (1,892 liters) for topical items, which it intends to extend to incorporate soft-gel suppositories by the close of Q1 2024 or the commencement of Q2 2024.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15942
Which geographic areas are influencing the growth of the topical drugs contract development and manufacturing organization (cdmo) market?
Asia-Pacific was the largest region in the topical drugs contract development and manufacturing organization (CDMO) market in 2023. The regions covered in the topical drugs contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024
Narcotic Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report
Biosimilar Therapeutic Peptides Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
